InMed Pharmaceuticals Inc. · NASDAQ:INM
InMed Pharmaceuticals — Corporate Update (April 2021)
22 slides from InMed Pharmaceuticals's corporate update, April 2021
Slide 1: Unlocking the Potential of Cannabinoid Medicines
UNLOCKING THE POTENTIAL OF CANNABINOID MEDICINES Company Webinar April 2021 :INM :IN *common shares to be delisted from www.inmedpharma.com the TSX on or about May 7, 2021
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) including, among others, statements concerning: unlocking the full potential of cannabinoid p
Slide 3: Today's Presenters
Today’s Presenters Eric A. Adams, MIBS Bruce S. Colwill, CPA, CA Chief Executive Officer Chief Financial Officer 30+ years of experience in global biopharma 25+ years of financial leadership with private leadership: business development, sales, and public companies; executing IPO, equity marketing,
Slide 4: A Differentiated Cannabinoid Pharmaceutical Company
A Differentiated Cannabinoid Pharmaceutical Company Focused on the Therapeutic Application of Cannabinoids for the Treatment of Diseases with High Unmet Medical Needs Researching the therapeutic potential of rare cannabinoids beginning with cannabinol (CBN) Selecting innovative, topically applied ca
Slide 5: Wide Range of Medicinal Properties
Wide Range of Medicinal Properties - Primarily based on non-clinical research THC Appetite loss Inflammation MOOD/BEHAVIOUR GASTRO-INTESTINAL CBC, CBD, CBDa, CBG, CBN, THC, THCa Anorexia Arthritis Cachexia CBC, CBD, CBN, THC, THCv Pain CBD, THC Gastrointestinal disorders PAIN/SLEEP CBC, CBD, CBN, TH
Slide 6: Tapping into the Potential of Rare Cannabinoids
Tapping into the Potential of Rare Cannabinoids <1% 2–20% 100+ Rare Cannabinoids Major Cannabinoids CBG, CBGA, CBGV, CBGVA, THC, THCA, THC CBD THCVA, CBC, CBCV, CBCVA, CBD, CBDA, CBC, CBCA, CBN, CBNA… • Epilepsy • Inflammation • The 100+ rare cannabinoids occur in extremely low amounts in the • Anxi
Slide 7: Progress with IntegraSyn
Progress with IntegraSyn™ 7
Slide 8: Limitations of Traditional Cannabinoid Production Approaches
Limitations of Traditional Cannabinoid Production Approaches EXTRACTION CHEMICAL SYNTHESIS BIOSYNTHESIS Access to rare May not produce bio- Bioburden/stress on cannabinoids identical cannabinoid microbe may limit final prohibitively expensive depending on cannabinoid yields complexity 8
Slide 9: IntegraSyn: Biosynthesis Evolved
IntegraSyn™: Biosynthesis Evolved IntegraSyn™ is InMed’s integrative cannabinoid manufacturing approach Minimizes bioburden Commonly available Flexibility Optimized steps to Transferable on fermentation and cost-efficient to shift from produce high-yield, technology microbe starting materials produc
Slide 10: IntegraSyn Achieves g/L Cannabinoid Yield
IntegraSyn™ Achieves 2 g/L Cannabinoid Yield 2021 • Achieved 2g/L cannabinoid yield with IntegraSyn™ • Signals commercial viability and supports large-scale production • Yields higher than current industry standards • Lowered overall manufacturing costs through process optimization • Enables a cost-
Slide 11: Targeting Pharmaceutical Quality
2021 Targeting Pharmaceutical Quality Cannabinoids More about GMP manufacturing types in the Learn section of our website.
Slide 12: IntegraSyn: High-level Time & Event Schedule
IntegraSynTM: High-level Time & Event Schedule 2021 Achieve 2g/L cannabinoid yield, signaling commercial viability Continue to identify potential partnerships for IntegraSynTM with commercial cannabinoid manufacturers Optimize pathways for production of additional cannabinoids Demonstrate end-to-end
Slide 13: INM-755 for Epidermolysis Bullosa (EB)
INM-755 for Epidermolysis Bullosa (EB) 11
Slide 14: Epidermolysis Bullosa (EB)
Epidermolysis Bullosa (EB) • Epidermolysis bullosa (EB) is a group of rare genetic skin diseases characterized by fragile skin that blisters easily from minimal friction that causes shearing of the skin layers. • The most common form is EB Simplex (EBS), ~55% of all EB patients. • The affected popul
Slide 15: Clinical Trial Applications Filed in Multiple Countries for Phase 2 in EB
Clinical Trial Applications Filed in Multiple Countries for Phase 2 in EB 2021 • CTA filings submitted in Austria, Israel, and Serbia for a Phase 2 Clinical Trial with INM-755 cream • Additional submissions slated for France, Germany, Greece, and Italy during the next several weeks. • Anticipated st
Slide 16: INM-755: High-Level Time/Event Schedule
INM-755: High-Level Time/Event Schedule 2021 Report results from 755-102-HV Finalize and file regulatory submissions (CTAs) for 755-201-EB trial Finalize manufacturing methods and process to support 755-201-EB Produce clinical trial supplies Initiate 755-201-EB trial in multiple European jurisdictio
Slide 17: INM-088 for Glaucoma
INM-088 for Glaucoma 14
Slide 18: Potential Roles for CBN in Glaucoma
Potential Roles for CBN in Glaucoma InMed data suggest CBN is the cannabinoid of choice for neuroprotection in the eye Target Effects of CBN Retina • Direct neuroprotection for the retina and optic nerve, independent of intraocular Pressure pressure (IOP) reduction Build Up of Optic • Reduce IOP in
Slide 19: INM-088: High-Level Time/Event Schedule
INM-088: High-Level Time/Event Schedule 2021 Engage leading ocular clinical research organization to develop clinical game plan Scale-up INM-088 drug product (CBN+MiDROPS®) Publish key CBN data in peer-reviewed journal Conduct non-GLP dose ranging studies Complete pre-IND package and FDA Pre-IND Mee
Slide 20: Business Development: Collaborations and Licensing
Business Development: Collaborations and Licensing Nature of Relationship InMed will explore the therapeutic potential in neuroprotection of specific cannabinoid analog compounds chosen from BayMedica’s library. BayMedica will assess the potential of InMed’s high-efficiency enzymes for the productio
Slide 21: Key Accomplishments and Goals
Key Accomplishments and Goals Highlights from 2020 Key Goals for 2021 INM-755 in Completed 2 Phase 1 human clinical trials Initiate and begin enrollment of EB patients in Dermatology (normal and wounded skin) Ph 2 trial Completed in vivo PoC, formulation/ Scaling-up manufacturing for drug product; I
Slide 22: Q&A Session
Q&A Session Eric A. Adams Bruce S. Colwill Edison Group Chief Executive Officer Chief Financial Officer Joseph Green jgreen@edisongroup.com eadams@inmedpharma.com bcolwill@inmedpharma.com Laine Yonker lyonker@edisongroup.com +1-604-669-7207 +1-604-669-7207 :INM :IN *common shares to be delisted from
InMed Pharmaceuticals — Corporate Update (April 2021) on 6ix